This designation was based on the fact that ATBF1 is located in the smallest region of overlap affected by loss of heterozygosity (LOH), and mutations were detected in prostate cancer cell lines, -xenografts, and -tumors [9]. This evidence concerns the gene ZFHX3 and prostate carcinoma.